FDA approves Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis knee pain.- Flexion Therapeutics.
Flexion Therapeutics, Inc.announced that the FDA approved Zilretta (triamcinolone acetonide extended-release injectable suspension), the first and only extended-release, intra-articular injection for osteoarthritis knee pain. Zilretta is a non-opioid medicine that employs Flexion's proprietary microsphere technology to provide proven pain relief over 12 weeks.
The FDA approval of Zilretta is based upon data from Flexion's pivotal Phase III clinical trial. The randomized, double-blind study enrolled 484 patients at 37 centers worldwide. Sometimes called degenerative joint disease or "wear and tear" arthritis, OA is a progressive and incurable condition and the most common form of arthritis. Its effects may range from intermittent discomfort to the loss of function and severe chronic pain associated with irreversible structural damage.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins